Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients

To evaluate the efficacy and safety of bendamustine combined with chidamide and lenalidomide in R/R PTCL patients.

Trial Details

NCT ID
NCT07072221
Phase
NA
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • BCL regimen
  • Cohort 1 (ASCT-eligible)
  • Cohort 2 (ASCT--ineligible)
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Age ≥18 years, male or female not limited;
  • Patients must have the capacity to understand and willingly provide written informed consent;
  • ECOG score 0-3 points;
  • Expected lifespan\>3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →